The independent source for health policy research, polling, and news.
1,181-1,200 of 1,325 results
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government’s ability to negotiate drug prices, but it’s not clear it would have much impact or will gain support.
Dentistry is at a crossroads and many in the field are reassessing their narcotics prescribing habits.
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
More than 30 states have laws on the books to allow dying patients the right to try experimental treatments. But these treatments may not be covered by insurance, and ethicists worry vulnerable people could be exploited near the end of their lives. The laws may also duplicate a process the FDA already has in place.
Hundreds of drug brands are being made in giant contract facilities. When a plant shuts down, a widespread drain on supply can result.
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.
Epinephrine, the active ingredient in EpiPens, expires after 18 months, and the auto-injector device can’t be refilled or reused. Health professionals are looking for work-arounds they say could save the health system millions.
An aging writer discovers there are worse things than going bald after examining the side effects of a popular hair loss drug purportedly used by President Donald Trump.
Aging adults with complex needs can get special assistance from doctors trained as geriatricians.
Some terminal patients, typically high-dose opioid users, who choose to end their lives have taken many hours, even days, to die.
The woman set to run the federal Centers for Medicare & Medicaid Services told senators last week that maternity coverage should be optional in individual and small group plans. But other services could also be left on the cutting room floor.
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
A study shows some emergency physicians wrote far more opioid prescriptions and Medicare patients who saw those doctors were more likely to still be taking the addictive painkillers months later.
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
Prescription pain pills are strong sellers in this southeastern Kentucky region that’s long struggled with high rates of joblessness and poor health.
Kaiser Health News reporter Shefali Luthra discusses the controversy surrounding Kaleo, a company that makes a life-saving auto-injector for opioid drug overdoses on Weekend Edition.
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
© 2026 KFF